Search Results
Jul 10, 2025, 07:49 ET CS Genetics Launches 96-Sample SimpleCell™ Kit, Delivering Same-Day Single Cell RNA-Seq at Population Scale
a radically new, instrument-free platform for single-cell genomics with disruptive simplicity, speed, and scalability that will launch a new era of NGS-based cellular analysis. The company's technology leverages a molecular process known as Kinetic Confinement that is categorically different to other
More news about: CS Genetics
Jul 08, 2025, 08:30 ET ePlus Named Digital Realty's 2024 Rising Star Partner of the Year
HERNDON, Va., July 8, 2025 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
Jul 07, 2025, 11:30 ET mRNA Sequencing Market Size to Hit USD 4.02 billion by 2031, Growing at 13.6% CAGR, Benefits from Surging Prevalence of Cancer | The Insight Partners
rise in cancer research and tests for the diagnosis of uncommon genetic abnormalities. There has been an upsurge in the adoption of new high-throughput NGS technologies—ThermoFisher's Ion Torrent and Illumina's NovaSeq—in various applications. The report from The Insight Partners provides several
More news about: The Insight Partners
Jul 03, 2025, 05:00 ET Novogene Europe amplía sus capacidades de secuenciación con la quinta plataforma NovaSeq X Plus en Europa
secuenciación de alto rendimiento para atender la creciente demanda en Europa. Esta mejora estratégica consolida la posición de Novogene como proveedor de NGS de confianza en Europa, ofreciendo una velocidad, calidad de datos y escalabilidad sin precedentes para proyectos de investigación a gran escala.
More news about: Novogene
Jul 02, 2025, 20:08 ET Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
simultaneously approved Thermo Fisher Scientific's Oncomine™ Dx Express Test as a next-generation sequencing (NGS) companion diagnostic (CDx) for ZEGFROVY to identify NSCLC patients with EGFR Exon20 insertions. NGS testing is recognized as a critical technology in cancer genomic profiling, facilitating the rapid
More news about: Dizal Pharmaceutical
Jul 01, 2025, 16:19 ET iconPCR™: Powering the Next Wave of Metagenomics and Microbiome Discovery
proven technologies to enhance workflow efficiency and sequencing reproducibility. A Platform for the Future of Microbiome ResearchAs NGS becomes ever more accessible and sample numbers scale into the thousands, the need for robust, automated, and bias-free library prep is only growing.
More news about: n6
Jul 01, 2025, 10:30 ET SeqOnce Biosciences - Expands Their Pathogen Assay Suite with the Addition of RT-qPCR Measles Panel
July 1, 2025 /PRNewswire/ -- SeqOnce, a company focused on the research, development, and commercialization of qPCR and NGS genomics tools for the Infectious Disease Research & CLIA Testing Market, has launched their new Measles Panel A.
More news about: SeqOnce Biosciences, Inc.
Jul 01, 2025, 07:15 ET ePlus Closes Sale of Financing Business to PEAC Solutions
HERNDON, Va., July 1, 2025 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: ePlus inc.
Jun 30, 2025, 14:14 ET North America LIMS Market to Reach $763.5 Million by 2032, Growing at a CAGR of 7.1% from 2025, Says Meticulous Research®
North America NGS Market: Global Analysis and Forecast Through 2032
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 11:43 ET In Vitro Diagnostics (IVD) Market to Reach $123.28 Billion by 2032, Growing at a CAGR of 5.5% from 2025, Says Meticulous Research®
Vitro Diagnostics (IVD) Market Size, Share, Forecast, & Trends Analysis by Offering (Kits) Technology (Immunoassay, Molecular Diagnostics [PCR, NGS] Rapid Test) Application (Infectious Diseases, Oncology) Diagnostic Approach (Lab, POC) - Global Forecast to 2032," the In Vitro Diagnostics
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 11:00 ET Whole Genome Sequencing Market to Reach $8.35 Billion by 2032, Growing at a CAGR of 15.4% from 2025, Says Meticulous Research®
genome sequencing providers, high awareness of genomic technologies, favorable government initiatives for genomics research, growing applications of NGS-based research, and favorable reimbursement scenarios. Asia-Pacific emerges as the fastest-growing region with
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 10:30 ET Neurogenomics Market to Reach $5.48 Billion by 2032, Growing at a CAGR of 17% from 2025, Says Meticulous Research®
Sequencing (NGS) segment dominates the market in 2025, capturing approximately 63% of the total market share due to recurring demand for consumables, increasing sequencing-based clinical and research applications of neurogenomics, and growing preference for sequencing-based diagnostics. The NGS segment
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 10:15 ET IVD Assay Development Market to Reach $9.15 Billion by 2032, Growing at a CAGR of 8.1% from 2025, Says Meticulous Research®
integration, precision medicine advancement, and development of personalized diagnostic solutions. Leading companies are embracing next-generation sequencing (NGS), high-throughput screening technologies, and genomic innovations while expanding into emerging markets and developing specialized assay development
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 08:43 ET Epigenica Closes $2.2 Million Investment Round to Scale Cutting-Edge Epigenetic Solutions
generate actionable insights to advance multi-omics and translational research, enable biomarker discovery, and accelerate next-generation sequencing (NGS) applications to improve human health. CorporateEpigenica CEO Mohamad Takwa, Ph.D.
More news about: Epigenica AB
Jun 26, 2025, 22:46 ET MGI ANNOUNCES PARTNERSHIP WITH NEGEDIA: ENHANCE GENOMIC SEQUENCING TECHNOLOGIES AT THE SERVICE OF SCIENTIFIC RESEARCH AND PRECISION MEDICINE IN ITALY
Negedia is an advanced genomics service laboratory supporting biomedical research through next-generation sequencing (NGS) and multi-omics technologies. Founded with the scientific support of Fondazione Telethon, Negedia provides researchers with high-quality, ready-to-publish
More news about: MGI TECH
Jun 26, 2025, 01:12 ET Illumina द्वारा SomaLogic का अधिग्रहण किया जाएगा, जिससे उसके प्रोटिओमिक्स बिज़नेस में तेजी आएगी और कंपनी की मल्टीओमिक्स रणनीति आगे बढ़ेगी
के सेक्वेंसिंग (NGS) प्लेटफ़ार्मों पर लाना है। वर्तमान में वैश्विक स्तर पर Illumina Protein Prep लगभग 40 शीघ्र-पहुंच वाले ग्राहकों के साथ उपयोग किया जा रहा है और 2025 की तीसरी तिमाही से यह सभी ग्राहकों के लिए उपलब्ध हो जाएगा। SomaLogic की प्रोटिओमिक्स टेक्नोलॉजी को Illumina के स्केलेबल NGS इकोसिस्टम, DRAGEN™
More news about: Illumina, Inc.
Jun 25, 2025, 08:00 ET Avance Biosciences Launches NGS Center of Excellence in Houston
advanced, cost-effective NGS testing domestically is now more feasible than ever. Our clients have confidence that their samples will remain in the U.S." Led by a multidisciplinary team of experts in molecular biology, genomics, assay development, and bioinformatics, the NGS Center of Excellence is
More news about: Avance Biosciences, Inc.
Jun 25, 2025, 00:48 ET Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
next-generation-sequencing (NGS) platforms. Illumina Protein Prep is currently in use with nearly 40 early-access customers globally and will become available to all customers starting in the third quarter of 2025. Combining SomaLogic's proteomics technology with Illumina's scalable NGS ecosystem, DRAGEN™ software,
More news about: Illumina, Inc.
Jun 24, 2025, 20:24 ET Zymo Research Unveils MultiOmiX Workstation with Show-Stopping Launch at ASM Microbe 2025
debut of the MultiOmiX Workstation, a next-generation platform delivering fully automated, high-throughput microbiome workflows – from sample through NGS-ready libraries.
More news about: Zymo Research Corp.
Jun 24, 2025, 10:56 ET Exclusive Outlook: HLA Typing Market Poised for 6.7% CAGR Growth Through 2030, Reaching $1.7 Billion on Rising Transplant Demand
significant growth. The rapid growth of the next-generation sequencing (NGS) has led to the rising adoption of HLA typing technologies that allow for high-resolution and high-throughput HLA typing with higher accuracy. The applications of NGS have made the HLA typing more effective in transplantation and personalized
More news about: The Research Insights
Jun 24, 2025, 08:30 ET ePlus Recognized as Innovator Partner of the Year at Pure Storage Annual Pure/Partner Forum
HERNDON, Va., June 24, 2025 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
Jun 23, 2025, 08:00 ET Gaia Dynamics Hits Major Milestone with AI Passing US Customs Classification Test with 100% Accuracy
Gaia Dynamics Gaia Dynamics is an AI-driven trade technology platform founded in 2025 in partnership with Andrew Ng's AI Fund. Headquartered in Palo Alto, California, the company leverages cutting-edge artificial intelligence to simplify
More news about: Gaia Dynamics
Jun 23, 2025, 07:15 ET ePlus Enters Into Agreement to Sell Financing Business to PEAC, a Portfolio Company of HPS Investment Partners, LLC
HERNDON, Va., June 23, 2025 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
Jun 23, 2025, 07:13 ET Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
next-generation-sequencing (NGS) platforms. Illumina Protein Prep is currently in use with nearly 40 early-access customers globally and will become available to all customers starting in the third quarter of 2025. Combining SomaLogic's proteomics technology with Illumina's scalable NGS ecosystem, DRAGEN™ software,
More news about: Illumina, Inc.
Jun 18, 2025, 19:45 ET Zymo Research Offers Reliable Domestic Solutions Amid Offshore Supply Chain Challenges
development partner, Zymo delivers high-quality, customizable solutions in sample collection, nucleic acid preservation and purification, reagents, enzymes, NGS library prep, plastics, and complete workflow design, all from its California headquarters.
More news about: Zymo Research Corp.